Abstract | BACKGROUND: METHODS: Patients were randomized to receive either nab-paclitaxel 100 mg/m2 on days 8 and 15 plus CC-486 200 mg daily on days 1 to 14 or single-agent nab-paclitaxel 100 mg/m2 on days 1 and 8, with both regimens administered every 21 days until tumor progression or unacceptable toxicity. The primary endpoint was progression-free survival. Secondary endpoints included the overall response rate, the disease control rate, and overall survival. RESULTS: Between January 2015 and August 2016, 161 patients were randomized (81 to the combination arm and 80 to the single-agent nab-paclitaxel arm). There was no benefit from the addition of CC-486 to nab-paclitaxel. The median progression-free survival was 3.2 months for the combination and 4.2 months for single-agent nab-paclitaxel (hazard ratio, 1.3; 95% confidence interval, 0.9-1.9). The median overall survival was 8.1 months in the combination arm and 17 months in the single-agent nab-paclitaxel arms (hazard ratio, 1.7; 95% confidence interval, 1.08-2.57). Grade 3 or greater treatment-related, emergent adverse events were reported by 40.5% of patients in the combination arm and by 31.6% of those in the single-agent nab-paclitaxel arm. CONCLUSIONS:
|
Authors | Daniel Morgensztern, Manuel Cobo, Santiago Ponce Aix, Pieter E Postmus, Conrad R Lewanski, Jaafar Bennouna, Jürgen R Fischer, Oscar Juan-Vidal, David J Stewart, Gianpiero Fasola, Andrea Ardizzoni, Rafia Bhore, Marianne Wolfsteiner, Denis C Talbot, Teng Jin Ong, Ramaswamy Govindan, On Behalf Of The Abound L Investigators |
Journal | Cancer
(Cancer)
Vol. 124
Issue 24
Pg. 4667-4675
(12 15 2018)
ISSN: 1097-0142 [Electronic] United States |
PMID | 30383906
(Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2018 American Cancer Society. |
Chemical References |
- 130-nm albumin-bound paclitaxel
- Albumins
- Antibodies, Monoclonal
- durvalumab
- Azacitidine
- Paclitaxel
|
Topics |
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Albumins
(administration & dosage, adverse effects)
- Antibodies, Monoclonal
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Azacitidine
(administration & dosage, adverse effects)
- Carcinoma, Non-Small-Cell Lung
(drug therapy)
- Disease-Free Survival
- Drug Administration Schedule
- Female
- Humans
- Lung Neoplasms
(drug therapy)
- Male
- Middle Aged
- Paclitaxel
(administration & dosage, adverse effects)
- Treatment Outcome
|